Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adverse Event Collection Expected To Be In Force By Christmas 2007

This article was originally published in The Tan Sheet

Executive Summary

Firms that make, pack or distribute dietary supplements and over-the-counter drugs approved under monographs will likely have to be in compliance with a new adverse event reporting law by late December 2007

You may also be interested in...



Robust Internal AER Systems Follow Supplement Lifecycle – Nature's Bounty Expert

Robust dietary supplement adverse event compliance systems can support faster identification of problems and improve products, says Nature’s Bounty Product Vigilance Manager Christina Romano. During a recent CRN webinar, she said distributors, retailers and researchers should be part of the reporting system.

Supplement Adverse Event Reports Sprout In Fertile Field Of Social Media

Compliance with FDA regulations on supplement marketers reporting serious adverse events means scrutinizing all information about a product on social media pages the same way a firm would comments that consumers or other parties submit by using contact information on product labeling.

Supplement AER Under-Reporting Marks Tip Of Compliance Iceberg – FDA

FDA’s dietary supplement program chief raised eyebrows at a botanical products conference citing low estimates on rates of compliance with the good manufacturing practices final rule and the new dietary ingredient notification requirements, as well as adverse event reporting.

Related Content

Topics

UsernamePublicRestriction

Register

PS100039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel